3 terminated, 2 completed. 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 3 | 2 | Terminated 2 |
Follow iron-magnesium hydroxycarbonate: new trials by email Literature Review of iron-magnesium hydroxycarbonate trials Research Report on iron-magnesium hydroxycarbonate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate Magnesium iron hydroxycarbonate, Lanthanum carbonate, Placebo - Chronic Kidney Failure | Phase 3 | Terminated | Ineos Healthcare Limited | 657 | 2009-07-01 | 2010-10-19 |
| Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride Fermagate, Sevelamer hydrochloride - Chronic Kidney Failure | Phase 3 | Terminated | Ineos Healthcare Limited | 1000 | 2009-07-01 | 2010-10-19 |
| Dose Ranging Study of Magnesium Iron Hydroxycarbonate in Haemodialysis Subjects With Hyperphosphataemia Fermagate, Sevelamer HCl - Chronic Kidney Failure | Phase 2 | Completed | Ineos Healthcare Limited | 64 | 2007-02-01 | 2009-08-10 |
| An Evaluation of the Long-term Safety of Magnesium Iron Hydroxycarbonate Fermagate - Chronic Kidney Failure | Phase 2 | Terminated | Ineos Healthcare Limited | 44 | 2006-07-01 | 2009-08-10 |
| Efficacy and Safety Study of Magnesium Iron Hydroxycarbonate for the Reduction of High Blood Phosphate in Hemodialysis Patients Fermagate, Placebo - Chronic Kidney Failure | Phase 2 | Completed | Ineos Healthcare Limited | 111 | 2006-03-01 | 2009-08-10 |
Kidney Failure, Chronic (5) · Hyperphosphatemia (4)
United Kingdom (4) · United States (4) · Brazil (2) · South Africa (2) · Australia (1) · Belgium (1) · Bulgaria (1) · Canada (1) · Czechia (1) · Estonia (1) · France (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1)
Simon Roe, MB ChB (2) · Maarten Taal, MBChB MD FRCP (1)
2008 (2)